ADVM-022

· Adverum Biotechnologies, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ADVM-022, covering 2025-04-22 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]